Ketone supplement shows promise for brain fog in early memory loss
NCT ID NCT06962501
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tested whether a single dose of an oral ketone supplement could increase blood flow and improve brain connectivity in 15 older adults with subjective or mild cognitive decline. Participants had one 2-hour session including MRI scans and cognitive tests. The goal is to see if this supplement might help support brain health in early memory problems.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- oral ketone monoester supplement
- What this could lead to
- If it works, this could point toward a simple dietary supplement that temporarily improves brain function in people with early memory problems.
- What could go wrong
- This is a very small, early pilot study with only 15 participants and a single dose. Results may not apply to long-term use or to the general population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
15 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
55 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged 55 years or older * Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI) SCD CRITERIA: * Self-experienced, persistent decline of cognitive abilities within the last 5 years in relation to a previously normal status * Normal results on demographically adjusted standardized cognitive tests * Accompanied by concerns associated with SCD and a feeling of worse performance than others in the same age group * Decline must not be related to a specific event or explained by a specific disease, medical disorder, medication, or substance abuse MCI CRITERIA * Fulfils criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5): * Demographically adjusted performance between -1 and -2 SD below average in one or more cognitive domains on standardized cognitive tests * Accompanied by concern from the individual, a knowledgeable informant, or clinician indicating mild cognitive decline * Capacity for independent daily activities is maintained Exclusion Criteria: * Clinical diagnoses of psychiatric disorders (e.g., anxiety disorders, depression) * Diagnosed major neurocognitive disorder (i.e., dementia) * Association of SCD or MCI with delirium * Diagnosed cardiometabolic disease (Uncontrolled hypertension (systolic blood pressure \>160 mm Hg, and/or diastolic blood pressure \>100 mm Hg, Type 2 diabetes) * Substance use disorder * History of heart attack or stroke requiring hospitalization in the past 3 years * MRI contraindications, including implanted medical devices * Experiencing residual fatigue, brain fog, or tiredness post-acute illness (i.e., long-COVID) * Severe literacy, visual, hearing, and/or speech impairment that would make participation in the study difficult or impossible * Individuals who are not fluent in Swiss German or German
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCI are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital of Basel
Basel, Canton of Basel-City, 4031, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new brain scan tracer aims to light up myelin damage
- Brain scans and genes may unlock early Alzheimer's detection
- Could a daily mushroom help shield aging brains?
- AI lifestyle coach may shield aging brains
- Could chatting with AI keep aging brains sharp?
- Hidden brain decline: are rehab wards overlooking cognitive problems?